FDA Grants Ibrutinib/Rituximab Priority Review for Waldenstrom Macroglobulinemia
The FDA has granted a priority review to a supplemental new drug application ibrutinib for use in combination with rituximab as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
Source: OncLive